Form 4: Royalty Pharma EVP Sells Over 135K Shares

Royalty Pharma's EVP of Investments & CLO, George W. Lloyd, sold 135,426 Class A Ordinary Shares for approximately $5.19 million under a pre-arranged 10b5-1 plan.

Summary

• George W. Lloyd, Executive Vice President of Investments and Chief Legal Officer at Royalty Pharma plc, reported the sale of 135,426 Class A Ordinary Shares.
• The sales occurred on November 19, 2025, through multiple transactions at weighted average prices ranging from $38.2787 to $39.0331 per share.
• The total value of the shares sold is approximately $5,192,220.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Lloyd on August 20, 2025.
• Following these transactions, Mr. Lloyd beneficially owns 1,010,627.19 Class A Ordinary Shares directly and indirectly.
• Additionally, Mr. Lloyd holds limited partnership interests exchangeable into 7,527,320 Class A Ordinary Shares and 1,944,471 Class E Ordinary Shares, some of which are subject to vesting conditions and may convert to Class A Ordinary Shares.

Sentiment

Score: 4

Explanation: While the sales were conducted under a 10b5-1 plan, which mitigates the negative signal, a significant divestment by a high-ranking executive can still be perceived with slight caution by the market. It's not overtly negative due to the pre-planned nature, but it's not a strong positive signal either.

Negatives

• A significant sale of shares by a key executive, even if pre-planned, can sometimes be perceived negatively by the market as it may suggest a desire to diversify personal holdings rather than a strong belief in immediate future stock appreciation.

Risks

• The market's perception of insider selling could lead to short-term negative pressure on the stock price.
• While executed under a 10b5-1 plan, large insider sales can sometimes be misinterpreted by investors as a signal regarding the company's future prospects, potentially impacting investor sentiment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide specific insights into broader industry trends or competitive landscape. However, insider selling activity is often monitored by investors as a data point within the broader context of a company's industry and market position.

Stakeholder Impact

• Shareholders may view the executive's sale of a substantial number of shares as a signal, potentially influencing their investment decisions, despite the existence of a 10b5-1 plan.

Key Dates

Recommendation

The filing reports a pre-planned insider sale, which is a routine disclosure. While large insider sales can sometimes raise questions, the existence of a 10b5-1 plan suggests the decision was made without reliance on new material non-public information. This single transaction, without additional context on company performance or strategic shifts, does not warrant a change from a 'hold' position for a seasoned investor. It's a data point to monitor but not a definitive buy or sell signal on its own.

Keywords

Royalty Pharma, RPRX, Insider Trading, Form 4, Stock Sale, Executive Transaction, George W. Lloyd, 10b5-1 Plan, Class A Ordinary Shares